Fluoxetine

Generic Name: Fluoxetine

Brand Names: Prozac, Sarafem, Symbyax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈F_₃NO

CAS Number: 54910-89-3

Unique Ingredient Identifier: 01K63SUP8D

Background: Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication: Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...

Associated Conditions: Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)

Associated Therapies: Maintenance therapy

Clinical Trials

Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder

Not Applicable

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Behavioral: Body in Mind Training (BMT)
Drug: Fluoxetine
Behavioral: Quality of Life Group

First Posted Date: 2017-03-07

Last Posted Date: 2019-02-27

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 200

Registration Number: NCT03072264

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

Phase 2

Completed

Conditions: Epilepsy
SUDEP

Interventions: Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2016-10-11

Last Posted Date: 2020-05-04

Lead Sponsor: Rup Kamal Sainju

Target Recruit Count: 30

Registration Number: NCT02929667

Locations: 🇺🇸
Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
The Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Measurement-based Care for Depression in Resource-Poor Settings

Phase 4

Completed

Conditions: Major Depression

Interventions: Behavioral: Enhanced Usual Care
Drug: Fluoxetine

First Posted Date: 2016-09-27

Last Posted Date: 2016-12-01

Lead Sponsor: Florida International University

Target Recruit Count: 140

Registration Number: NCT02916238

Locations: 🇭🇹
GHESKIO Centers, Port-au-Prince, Haiti

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: Placebo
Drug: Fluoxetine
Radiation: fMRI

First Posted Date: 2016-05-11

Last Posted Date: 2023-08-28

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 25

Registration Number: NCT02767999

Locations: 🇫🇷
CHU Toulouse, Toulouse, France
🇫🇷
Hôpital Pellegrin, Bordeaux, France

The Staged Treatment in Early Psychosis Study

Phase 3

Conditions: Psychotic Disorders
Personality Disorders
Clinical High Risk

Interventions: Behavioral: 3-monthly monitoring
Behavioral: Support and Problem Solving Therapy
Behavioral: Cognitive Behavioural Case Management
Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2016-04-26

Last Posted Date: 2020-09-16

Lead Sponsor: Orygen

Target Recruit Count: 340

Registration Number: NCT02751632

Locations: 🇦🇺
Orygen Youth Health Clinical Program, Melbourne, Victoria, Australia
🇦🇺
Headspace, Werribee, Victoria, Australia

Fluoxetine for Visual Recovery After Ischemic Stroke

Phase 2

Terminated

Conditions: Acute Stroke
Visual Field Loss

Interventions: Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2016-04-14

Last Posted Date: 2021-10-13

Lead Sponsor: Bogachan Sahin

Target Recruit Count: 17

Registration Number: NCT02737930

Locations: 🇺🇸
Strong Memorial Hospital, Rochester, New York, United States

Hierarchical Treatment Based on Somatization Symptom Checklist

Phase 1

Conditions: Syndrome X

Interventions: Procedure: coronary artery disease treatment
Drug: Deanxit
Drug: Prozac

First Posted Date: 2016-03-31

Last Posted Date: 2020-03-04

Lead Sponsor: RenJi Hospital

Target Recruit Count: 200

Registration Number: NCT02723903

Locations: 🇨🇳
Renji Hospital, Shanghai, China

Efficacy of Fluoxetine - a Trial in Stroke

Phase 3

Completed

Conditions: Stroke

Interventions: Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2016-02-17

Last Posted Date: 2020-09-02

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 1500

Registration Number: NCT02683213

Locations: 🇸🇪
Karolinska Institutet, Stockholm, Sweden

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

First Posted Date: 2016-01-14

Last Posted Date: 2021-07-02

Lead Sponsor: University of Washington

Target Recruit Count: 635

Registration Number: NCT02655354

Locations: 🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Honor Health, Scottsdale, Arizona, United States

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy